Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004393 · ClinicalTrials.gov registry record · Phase 2
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
A Phase 2 study of Neoplasms and Opioid-Related Disorders, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01004393 is a Phase 2 study of Neoplasms and Opioid-Related Disorders that has completed, run by University of Vermont. The registered enrollment target is 12 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01004393, a Phase 2 study of Neoplasms and Opioid-Related Disorders, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
Conditions Studied
Interventions
- DRUG Methylnaltrexone bromide
Study Locations (1)
Vermont
- Fletcher Allen Health Care - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004393
The ClinicalTrials.gov registry entry for NCT01004393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Methylnaltrexone bromide is the first listed.
NCT01004393 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT01004393 about?
NCT01004393 is a clinical study titled "Methylnaltrexone for Opioid-induced Constipation in Cancer Patients". The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
What is the current status of trial NCT01004393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2009-10. Estimated completion is 2013-12.
What conditions does trial NCT01004393 study?
This clinical trial studies the following conditions: Neoplasms, Opioid-Related Disorders, Constipation.
What interventions are being tested in trial NCT01004393?
The interventions under investigation include: Methylnaltrexone bromide (DRUG).
Who is sponsoring clinical trial NCT01004393?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01004393 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.